结直肠癌肝转移的诊断与治疗进展

doi:10.3969/j.issn.1672-3384.2015.03.003

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1117 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：综述结直肠癌肝转移的诊断与治疗进展。方法：查阅国内外公开发表的文献进行综述。结果与结论 ：结直肠癌是临床常见的恶性肿瘤，结直肠癌肝转移是影响结直肠癌预后的主要因素。传统上，CT 最常用于结直肠癌肝转移的术前评估与分期。结直肠癌肝转移的治疗目前提倡综合治疗，以手术为核心，辅以化疗、靶向治疗、局部治疗等。结直肠癌肝转移的治疗进步一直得益于多学科综合治疗水平的提高和发展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	肖艳琼
	陈潇
	张涛

关键词 ：结直肠癌, 肝转移, 诊断, 治疗

Abstract：Objective : To summarize the diagnosis and the treatment of colorectal cancer liver metastasis. Methods : Review of lastest researchs related to the diagnosis and the treatment of colorectal cancer liver metastasis. Results and conclusion : Colorectal cancer is a commom malignant tumor. Liver metastasis is the main factor affecting prognosis of colorectal cancer. Traditionally, computed tomographic imaging (CT) is utilized for staging and evaluating the metastatic lesions in the liver. In nowadays,the treatment of colorectal cancer liver metastasis (CRLM) is comprehensive,with surgery to be the core treatment, as well as the chemotherapy, targeted therapy, localtreatment to be the complements. The progress of CRLM treatment is profitted from the improvement and the development of the multimodality treatment.

Key words： colorectal cancer liver metastases diagnose therapy

收稿日期: 2015-01-20

R735.3

基金资助:重庆市渝中区科技计划项目（20110323）和国家临床重点专科肿瘤学建设项目（国卫办医函[2013]544 号）

通讯作者: 张涛 E-mail: xiaoyanqiong008@163.com

引用本文:

肖艳琼，陈潇，张涛. 结直肠癌肝转移的诊断与治疗进展[J]. 临床药物治疗杂志, 2015, 13(3): 9-13.
XIAO Yan-qiong，CHEN Xiao，ZHANG Tao. Progress in diagonisis and treatment of colorectal cancer liver metastasis. CLINICAL MEDICATION JOURNAL, 2015, 13(3): 9-13.

链接本文:

http://www.lcywzlzz.com/CN/10.3969/j.issn.1672-3384.2015.03.003 或 http://www.lcywzlzz.com/CN/Y2015/V13/I3/9

[1] 秦新裕，冯青阳，许剑民. 重视并规范化开展结直肠癌肝转移多学科综合治疗[J]. 中国实用外科杂志, 2013, 33(8)：619-621.
[2] Minami Y, Kudo M. Radiofrequency ablation of liver metastases from colorectal cancer: a literature review[J]. Gut Liver, 2013, 7(1):1-6.
[3] 许剑民，任黎. 结直肠癌肝转移诊断和综合治疗指南（V2013）[J].中国实用外科杂志, 2013, 33(8)：635-644.
[4] Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer:a systematic review and meta-analysis[J].J Magn Reson Imaging,2010, 31(1):19-31.
[5] van Kessel C S, Buckens C F, van den Bosch M A,et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-Analysis[J].Ann Surg Oncol, 2012,19(9):2805-2813.
[6] 黄利利，李梅，程志斌. 普美显在肝脏疾病诊断中的应用现状[J].中国普通外科杂志, 2013, 22(7 ):938-943.
[7] Muhi A, Ichikawa T, Motosugi U, et al.Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxideenhanced MRI, and gadoxetic acidenhanced MRI[J].J Magn Reson Imaging, 2011, 34(2):326-335.
[8] Donat O F, Hany T F, Reiner C S,et al.Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI[J]. J Nucl Med, 2010, 51(5):692-699.
[9] Berger-Kulemann V, Schima W, Baroud S, et al.Gadoxetic acidenhanced 3.0T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopatholgy as a standard of reference[J]. Eur J Surg Oncol, 2012, 38(8):670-676.
[10] Chen L , Zhang J, Zhang L, et al. Meta-analysis of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastases[J]. PLoS One, 2012,7(11):e48681.
[11] 蔡建强, 毕新宇, 李原. 结直肠癌肝转移外科治疗策略[J]. 中国实用外科杂志, 2013, 33(8)：628-630.
[12] 钟芸诗, 朱德祥, 韦烨, 等. 结直肠癌肝转移灶手术指征拓展临床应用评价—中国《结直肠癌肝转移诊断和综合治疗指南（V2010）》应用体会[J]. 中国实用外科杂志, 2013, 33(8):676-679.
[13] Nordlinger B, Sorbye H, Glimelius B, et al.Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial[J]. Lancet,2008, 371(9617): 1007-1016.
[14] Nordlinger B, Sorbye H, Glimelius B,et al.Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial [J].Lancet Oncol, 2013,14(12): 1208-1215.
[15] Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel[J]. Ann Oncol, 2009, 20(6): 985-992.
[16] Haraldsdottir S, Wu C, Bloomston M, et al. What is the optimal neoadjuvant treatment for liver metastasis?[J]. Ther Adv Med Oncol,2013, 5(4): 221-234.
[17] 吴斌，杨金坤，朱莹杰. 潜在可切除结直肠癌肝转移转化治疗的研究进展[J]. 世界华人消化杂志, 2014, 22(4): 533-540.
[18] Van Cutsem E, K?hne C H, Hitre E,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J med, 2009, 360(14): 1408-1417.
[19] Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil,leucovorin, and oxaliplatin with and without cetuximab in the firstline treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2009,27(5): 663-671.
[20] Maughan T S, Adams R A, Smith C G, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial[J]. Lancet, 2011, 377(9783): 2103-2114.
[21] Tveit K M, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study[J]. J Clin Oncol, 2012, 30(15): 1755-1762.
[22] Venook A P, Niedzwiecki D, Lenz H J, et al.CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)[J].J Clin Oncol, 2014, 32(15 suppl): LBA3.
[23]Hurwitz H, Fehrenbacher L, Novotny W, et al .Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J] N Engl J med, 2004, 350(23): 2335-2342.
[24] Saltz L B, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study[J]. J Clin Oncol, 2008, 26(12): 2013-2019.
[25] Falcone A, Cremolini C, Masi G, et al. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group[C]. J Clin Oncol, 2013, 31(15 suppl): 3505.
[26] Michl M, Fischer von Weikersthal L,Crispin A,et al.AIO KRK0306,FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab [J]. J Clin Oncol, 2014, 32(15 suppl):3592.
[27] Goyer P, Karoui M, Vigano L, et al. Single-center multidisciplinary management of patients with colorectal cancer and resectable synchronous liver metastases improves outcomes[J]. Clin Res Hepatol Gastroenterol, 2013, 37(1): 47-55.